Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardio Catch-Up: More Conferences, More New Data From Abbott And Medtronic

Executive Summary

Medtech Insight’s Cardiovascular Catch-Up highlights some of the recent news on cardiovascular tech innovations in the last two months. This edition focuses on news from conferences, held over the last two months, including the Heart Rhythm Society and the TVT Structural Heart Summit.

You may also be interested in...



Digital Health Roundup: Solutions For Heart, Loneliness; Diabetes Talks; Post-Roe Legal Advice

In this month’s Digital Health roundup, Medtech Insight’s Barnaby Pickering discusses DeHealth, which developed a platform built on cryptocurrency, and executive interviews with Glooko and Omada Health about their diabetes platforms. Marion Webb will highlight a conversation with Nixon Gwilt Law attorney Bethany Corbin about key steps developers of period-tracking apps can take to ensure that sensitive health data remains safe and private. Reed Miller discusses Braidio’s health information platform and Pyx Health’s hybrid solution for loneliness.

Cardiovascular Catch-Up: ACC Brings Encouraging Renal Denervation And TAVR Data For Medtronic

Medtech Insight’s Cardiovascular Catch-Up highlights recent news and insights from cardiovascular device companies – big and small – from the last few weeks. This edition focuses on news from the recent American College of Cardiology Scientific Sessions.

Abbott Becomes Third US TAVR Competitor With Portico Approval

Portico with the FlexNav delivery system earned FDA approval for people with symptomatic, severe aortic stenosis who would be at high or extreme risk in open-heart surgery.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel